Top

Published in:

01-02-2017 | Editorial

Anthracycline-induced cardiomyopathy: The search continues

Authors: Agnes S. Kim, MD, PhD, Steven R. Bergmann, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 1/2017

Excerpt

Anthracyclines are not only some of the most effective, but also the most toxic, chemotherapeutic agents. Their use is associated with a dose-dependent, progressive, dilated cardiomyopathy. To date, there is no specific laboratory or imaging approach to proactively identify patients who will develop anthracycline-induced cardiotoxicity. Echocardiography and radionuclide ventriculography have been employed to measure left ventricular ejection fraction as chemotherapy progresses, and once decreases in function are identified, chemotherapy dosage or frequency is modified, or the chemotherapy is stopped. Unfortunately, overt cardiomyopathy is a late manifestation of injury due to anthracyclines,1 and thus prediction of which patients may develop anthracycline-induced cardiac toxicity is an important goal, especially since these agents are frequently used in children and young adults. …

Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.CrossRefPubMed

Horenstein MS, Vander Heide RS, L’Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 2000;71:436-44.CrossRefPubMed

Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213-25.CrossRefPubMed

Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009;61:154-71.CrossRefPubMed

Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001;68:889-901.CrossRefPubMed

Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003;93:105-15.CrossRefPubMed

Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007;67:8839-46.CrossRefPubMed

Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu LS, Liu YL, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-42.CrossRefPubMed

Maeda A, Honda M, Kuramochi T, Takabatake T. Doxorubicin cardiotoxicity: Diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes. Jpn Circ J 1998;62:505-11.CrossRefPubMed

10.

Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 2003;35:1473-9.CrossRefPubMed

11.

De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010;121:276-92.CrossRefPubMed

12.

Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324(12):808-15.CrossRefPubMed

13.

Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association. Circulation 2013;128:1927-95.CrossRefPubMed

14.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-80.CrossRefPubMedPubMedCentral

15.

Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 2009;158:294-301.CrossRefPubMed

16.

Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR, et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr 2011;12:945-52.CrossRefPubMed

17.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.CrossRefPubMedPubMedCentral

18.

Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30:1042-9.CrossRefPubMedPubMedCentral

19.

Valdes Olmos RA, ten Bokkel Huinink WW, Greve JC, Hoefnagel CA. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med 1992;17:163-7.CrossRefPubMed

20.

Wakasugi S, Wada A, Hasegawa Y, Nakano S, Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 1992;33:208-14.PubMed

21.

Takeishi Y, Sukekawa H, Sakurai T, Saito H, Nishimura S, Shibu T, et al. Noninvasive identification of anthracycline cardiotoxicity: Comparison of 123I-MIBG and 123I-BMIPP imaging. Ann Nucl Med 1994;8:177-82.CrossRefPubMed

22.

Carrió I, Estorch M, Berná L, López-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.PubMed

23.

Estorch M, Carrió I, Berná L, López-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol 1995;2:126-32.PubMed

24.

Ji SY, Travin MI. Radionuclide imaging of cardiac autonomic innervation. J Nucl Cardiol 2010;17:655-66.CrossRefPubMed

25.

Soman P, Travin MI, Gerson M, Cullom SJ, Thompson R. I-123 MIBG cardiac imaging. J Nucl Cardiol 2015;22:677-85.CrossRefPubMed

26.

Slomka PJ, Mehta PK, Germano G, Berman DS. Quantification of I-123-meta-iodobenzylguanidine heart-to-mediastinum ratios: Not so simple after all. J Nucl Cardiol 2014;21:979-83.CrossRefPubMed

27.

Travin M. Cardiac autonomic imaging with SPECT tracers. J Nucl Cardiol 2013;20:128-43.CrossRefPubMed

28.

Dos Santos MJ, da Rocha ET, Verberne HJ, da Silva ET, Aragon DC, Junior JS. Assessment of late anthracycline-induced cardiotoxicity by ¹²³I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence. J Nucl Cardiol 2015. doi:10.1007/s12350-015-0309-y.PubMed

29.

Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol 2013;20:443-64.CrossRefPubMed

Title: Anthracycline-induced cardiomyopathy: The search continues
Authors: Agnes S. Kim, MD, PhD
Steven R. Bergmann, MD, PhD
Publication date: 01-02-2017
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 1/2017
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0352-8

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anthracycline-induced cardiomyopathy: The search continues

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results

Erratum to: Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism?

Multimodality Imaging: Bird’s-Eye View from the 65th Annual Scientific Sessions of the American College of Cardiology, Chicago, Ill, April 2–4, 2016

Advances in image reconstruction software in nuclear cardiology: Is all that glitters gold?

Current status of nuclear cardiology practice in Latin America and the Caribbean

Erratum to: What do we know? What do we need to know?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page